{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120261","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.015366+00:00","generated_at":"2026-05-21T05:35:52.441593+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd Q1 net revenue $11.3M; net loss narrows to $16.3M; targets 1H 2025 profitability","bullets":["PEMGARDA net product revenue of $11.3M in Q1 2025, down from $13.8M in Q4 2024 due to sales force transition; re-acceleration seen in Q2 2025.","Net loss of $16.3M ($0.14 per share) vs $43.5M ($0.38) a year ago; R&D expenses fell to $10.6M from $31.2M.","Cash and equivalents $48.1M as of March 31 2025; secured $30M non-dilutive term loan facility with Silicon Valley Bank in April 2025.","FDA declined EUA expansion request for PEMGARDA as a treatment in Feb 2025 but provided potential near-term pathway for VYD2311.","VYD2311 Phase 1 data read-out (potency, half-life, safety) anticipated later in Q2 2025; pipeline expansion into RSV and measles underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120261","json":"https://secwatch.observer/filing/0001193125-25-120261.json","markdown":"https://secwatch.observer/filing/0001193125-25-120261.md","text":"https://secwatch.observer/filing/0001193125-25-120261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/0001193125-25-120261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/d66861d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:35:52.441593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}